Page last updated: 2024-11-06

mizolastine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Mizolastine is a non-sedating antihistamine that was once marketed for the treatment of allergic rhinitis. It was withdrawn from the market in several countries due to the risk of serious cardiac arrhythmias, particularly torsades de pointes. Mizolastine is a potent antagonist of the histamine H1 receptor. It is rapidly absorbed after oral administration and is extensively metabolized in the liver. The main metabolite of mizolastine, desmizolastine, is also a potent H1 antagonist and contributes to the drug's antihistaminic activity. Mizolastine is a racemic mixture of two enantiomers, only one of which is pharmacologically active. The active enantiomer is the S-enantiomer. The R-enantiomer is inactive and is thought to be responsible for the cardiotoxicity of mizolastine. Mizolastine has been studied extensively in preclinical and clinical trials. Preclinical studies have shown that mizolastine is a potent antihistamine with a long duration of action. Clinical trials have confirmed the efficacy of mizolastine in the treatment of allergic rhinitis. However, the risk of torsades de pointes has led to the withdrawal of mizolastine from the market in several countries. Mizolastine is still available in some countries, but it is often used off-label for the treatment of other conditions, such as chronic urticaria. However, the use of mizolastine should be avoided in patients with a history of heart problems or who are taking other medications that can prolong the QT interval. The synthesis of mizolastine involves several steps, including the coupling of a substituted phenylacetic acid with a substituted piperidine derivative.'

Cross-References

ID SourceID
PubMed CID65906
CHEMBL ID94454
CHEBI ID31857
SCHEMBL ID5061
MeSH IDM0204949

Synonyms (83)

Synonym
AC-634
4(1h)-pyrimidinone, 2-((1-(1-((4-fluorophenyl)methyl)-1h-benzimidazol-2-yl)-4-piperidinyl)methylamino)-
mizolastine [inn]
c24h25fn6o
sl 85.0324
2-((1-(1-(p-fluorobenzyl)-2-benzimidazolyl)-4-piperidyl)methylamino)-4(3h)-pyrimidinone
mizolastina [inn-spanish]
mizolastinum [inn-latin]
mizolastine
zolistam
mkc-431
zolim
mizolen
sl-85.0324
zolistan
mizollen
chembl94454 ,
2-[(1-{1-[(4-fluorophenyl)methyl]-1h-1,3-benzodiazol-2-yl}piperidin-4-yl)(methyl)amino]-3,4-dihydropyrimidin-4-one
2-({1-[1-(4-fluoro-benzyl)-1h-benzoimidazol-2-yl]-piperidin-4-yl}-methyl-amino)-3h-pyrimidin-4-one
2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)piperidin-4-yl)(methyl)amino)pyrimidin-4(3h)-one
bdbm22877
NCGC00181013-01
mizolastine (jan/inn)
mizollen (tn)
108612-45-9
D01117
2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-1h-pyrimidin-6-one
AKOS005145756
mistamine
mistalin
sl 850324
2-[[1-[1-[(4-fluorophenyl)methyl]-2-benzimidazolyl]-4-piperidinyl]-methylamino]-1h-pyrimidin-6-one
A801901
2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methyl-amino]-1h-pyrimidin-6-one
mizolastinum
244o1f90na ,
ccris 8410
mizolastine [inn:ban]
mizolastina
unii-244o1f90na
cas-108612-45-9
dtxsid5046801 ,
tox21_112663
dtxcid3026801
AKOS016003409
FT-0628955
2-[[1-[1-[(4-fluorophenyl)methyl]benzoimidazol-2-yl]-4-piperidyl]-methyl-amino]-3h-pyrimidin-4-one
BRD-K21884483-001-01-1
CCG-220621
HY-B0164
CS-1997
smr003965484
MLS006010068
SCHEMBL5061
NCGC00344565-01
tox21_112663_1
KS-1139
PVLJETXTTWAYEW-UHFFFAOYSA-N
2-({1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-piperidin-4-yl}-methylamino)-4(1h) pyrimidinone
mizolastine [mart.]
mizolastine [jan]
mizolastine [who-dd]
mizolastine [mi]
M2756
AB01566892_01
J-507624
CHEBI:31857
NCGC00344565-04
HMS3713N04
2-{1-[1-(4-fluorobenzyl)-1h-benzimidazol-2-yl]-4-piperidyl(methyl)amino}pyrimidin-4(1h)-one
DB12523
Q417830
(4-ethoxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-aceticacid
mizolastine (mizollen)
2-((1-(1-(4-fluorobenzyl)-1h-benzo[d]imidazol-2-yl)-piperidin-4-yl)(methyl)amino)pyrimidin-4(1h)-one
mfcd23140913
gtpl10102
sl-850324
mkc431
sl850324
T71584
EN300-7396250
2-[[1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]- methylamino]-1h-pyrimidin-6-one

Research Excerpts

Overview

Mizolastine is a nonsedating H1 histamine receptor antagonist with additional antiallergic properties currently marketed in Europe for the treatment of seasonal and perennial allergic rhinitis (PAR) and urticaria. In in-vitro animal models, mizolstine was shown to inhibit 5-lipoxygenase activity.

ExcerptReferenceRelevance
"Mizolastine is a nonsedating H1 histamine receptor antagonist with additional antiallergic properties currently marketed in Europe for the treatment of seasonal and perennial allergic rhinitis (PAR) and urticaria."( Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine.
Antosova, E; Bachert, C; Frèche, C; Goos, M; Gracia, FD; Hide, D; Horak, F; Horvath, A; Leynadier, F; Soussen, PB; Verrecchia, M, 2002
)
3.2
"Mizolastine is a potent and selective H1-receptor antagonist with antiallergic properties; in in-vitro animal models, mizolastine was shown to inhibit 5-lipoxygenase activity and to decrease the release of leukotrienes (LT) and tumor necrosis factor-alpha (TNF-alpha). "( Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine.
Ben-Soussen, P; Bousquet, J; Carayol, N; Crampette, L; Lebel, B; Mainprice, B; Verrecchia, M, 2002
)
1.98
"Mizolastine is a new, nonsedating antihistamine under clinical investigation for treatment of allergic rhinitis and urticaria."( Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.
Attali, P; Bousquet, J; Leynadier, F; Murrieta, M, 1996
)
2.05
"Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic rhinitis and urticaria. "( Lack of subsensitivity to mizolastine over 8-week treatment.
Bousquet, J; Chanal, I; Murrieta, M; Stalla-Bourdillon, A, 1996
)
2.04
"Mizolastine is a new, non-sedating antihistamine providing satisfactory symptomatic relief in seasonal allergic rhinitis. "( Comparison of mizolastine with loratadine in the treatment of perennial allergic rhinitis.
Bellioni, P; Carraro, A; Catalano, B; Cervellera, G; Filiaci, F; Mira, E, 1996
)
2.1
"Mizolastine is a new, nonsedating antihistamine providing satisfactory symptomatic relief in allergic rhinitis and urticaria. "( Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine.
Cabanis, MJ; Caplain, H; Dubruc, C; Pinquier, JL; Rosenzweig, P; Stalla-Bourdillon, A, 1996
)
1.97
"Mizolastine is a new, nonsedating antihistamine providing satisfactory symptom relief in allergic conditions. "( Can an antihistamine delay appearance of hay fever symptoms when given prior to pollen season?
Darnell, R; Stern, MA; Tudor, D, 1997
)
1.74
"Mizolastine is a new, nonsedating antihistamine with additional anti-inflammatory properties, providing relief in allergic rhinitis and urticaria. "( Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group.
Bachert, C; Brostoff, J; Murrieta, M; Scadding, GK; Stalla-Bourdillon, A; Tasman, J, 1998
)
3.19
"Mizolastine is a novel histamine H1-antagonist registered in Europe for the management of allergic rhinitis and urticaria."( Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.
Dubertret, L; Murrieta Aguttes, M; Tonet, J, 1999
)
2.06
"Mizolastine is a new non-sedating antihistamine with antiallergic properties."( The current cardiac safety situation with antihistamines.
Camm, AJ; Yap, YG, 1999
)
1.02
"Mizolastine is a potent, selective, nonsedating peripherally acting H1-receptor antagonist which is registered for rhinitis and urticaria at a recommended dose of 10 mg once daily."( Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
Caplain, H; Chaufour, S; Deschamps, C; Dubruc, C; L'héritier, C; Lilienthal, N; Rosenzweig, P, 1999
)
1.26
"Mizolastine is a potent and selective H1-receptor antagonist which slowly penetrates into the brain and thus lacks the sedative effects of earlier antihistamines."( Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies.
Patat, A; Rosenzweig, P, 1999
)
1.31
"Mizolastine is a potent and selective H1-receptor antagonist with additional anti-allergic properties."( Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group.
Attali, P; Ben-Soussen, P; Daele, J; Sabbah, A; Wade, AG, 1999
)
1.99
"Mizolastine appeared to be a relatively weak and unspecific inhibitor of CYP2E1, CYP2C9, CYP2D6 and CYP3A4 (IC50Ss in the 100 micromolar range)."( In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines.
Collart, P; Nicolas, JM; Roba, J; Whomsley, R, 1999
)
1.02
"Mizolastine is a new non-sedative antihistamine and antiallergic drug proven to be effective and safe in the treatment of allergic rhinitis and urticaria."( Humoral and cellular responses to histamine and pollen allergen in a skin chamber model: effect of mizolastine.
Dubertret, L; Jean-Louis, F; Levy, D; Michel, L; Murrieta-Aguttes, M, 2000
)
1.97
"Mizolastine is a novel second generation antihistamine with additional anti-inflammatory properties which has been shown to be effective in this condition as well as in allergic rhinitis. "( One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group.
Giannetti, A; Leynadier, F; Lorette, G; Murrieta-Aguttes, M; Pereira, RS, 2000
)
2.01
"Mizolastine is a potent, peripherally acting, selective H1-receptor antagonist with potential anti-inflammatory properties. "( Effects of mizolastine in vitro on human immunocompetent and airway cells: evidence for safety and additional property.
Cagnoni, F; Canonica, GW; Dellacasa, P; Oddera, S, 2000
)
2.14
"Mizolastine is a second-generation antihistamine that has been shown, in experimental studies, to possess 5-lipoxygenase inhibitory properties in addition to its H1-receptor antagonistic activity."( Clinical advantages of dual activity in allergic rhinitis.
Horak, F, 2000
)
1.03
"Mizolastine is a second generation antihistamine agent approved in Europe for the treatment of allergic rhinitis and skin conditions for which Sanofi-Synthélabo is developing a pediatric solution. "( Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Dubruc, C; Mentré, F; Thénot, JP, 2001
)
1.98
"Mizolastine is a new histamine H1 receptor antagonist. "( Clinical pharmacokinetics of mizolastine.
Chosidow, O; Diquet, B; Lebrun-Vignes, B, 2001
)
2.04

Effects

Mizolastine has also been shown to be an effective treatment for cold-induced urticaria, causing significant delay in the whealing response to the ice-cube test and also reducing the wheal diameter.

ExcerptReferenceRelevance
"Mizolastine has also been shown to be an effective treatment for cold-induced urticaria, causing significant delay in the whealing response to the ice-cube test and also reducing the wheal diameter."( Clinical advantages of dual activity in urticaria.
Kontou-Fili, K, 2000
)
1.03
"Mizolastine has also been shown to be at least as effective as loratadine, and in one trial even superior in the treatment of perennial allergic rhinitis."( Clinical advantages of dual activity in allergic rhinitis.
Horak, F, 2000
)
1.03

Actions

ExcerptReferenceRelevance
"Mizolastine might inhibit the production of LTB(4) and IL-5 induced by substance P in mouse skin, suggesting that anti-inflammatory effect and the blockade of histamine H1 receptors might be involved in its anti-pruritic mechanisms."( [Inhibitory effects of mizolastine on substance P-induced production of leukotriene B4 and interleukin 5 in mouse skin].
Fang, H; Wang, YN; Yao, HP; Zhou, ZL, 2006
)
2.09

Treatment

Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0.001) and at the end of the treatment period (-46%, P = 0.01) Mizolastin-treated patients showed significantly greater alleviation of nasal symptoms, with a mean decrease of 36% compared with pretreatment score.

ExcerptReferenceRelevance
"Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0.001) and at the end of the treatment period (-46%, P = 0.01), and significantly greater than that observed with loratadine at D14 (P = 0.031). "( Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine.
Antosova, E; Bachert, C; Frèche, C; Goos, M; Gracia, FD; Hide, D; Horak, F; Horvath, A; Leynadier, F; Soussen, PB; Verrecchia, M, 2002
)
3.2
"Mizolastine-treated patients showed significantly greater alleviation of nasal symptoms, with a mean decrease of 36% compared with pretreatment score, compared to a mean decrease of 10% in placebo patients (P < 0.001). "( Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group.
Bachert, C; Brostoff, J; Murrieta, M; Scadding, GK; Stalla-Bourdillon, A; Tasman, J, 1998
)
3.19

Toxicity

Mizolastine was shown to be free from sedative effects that could affect the safe performance of everyday life activities in young and aged patients. Adverse events were slightly more frequent in the 15-mg group.

ExcerptReferenceRelevance
" Adverse events were slightly more frequent in the 15-mg mizolastine group."( Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group.
Attali, P; Bousquet, J; Leynadier, F; Murrieta, M, 1996
)
0.85
" Thus, although the post-marketing experience with mizolastine is still limited, mizolastine offers a safe alternative for the therapeutic management of allergic rhinitis and urticaria."( The current cardiac safety situation with antihistamines.
Camm, AJ; Yap, YG, 1999
)
0.56
" Mizolastine was shown to be free from sedative effects that could affect the safe performance of everyday life activities in young and aged patients when administered at the therapeutic dose."( Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies.
Patat, A; Rosenzweig, P, 1999
)
1.5
" Safety was assessed according to the spontaneous reporting of adverse events."( Comparison of the efficacy, safety, and onset of action of mizolastine, cetirizine, and placebo in the management of seasonal allergic rhinoconjunctivitis. MIZOCET Study Group.
Attali, P; Ben-Soussen, P; Daele, J; Sabbah, A; Wade, AG, 1999
)
0.55
" Both compounds were well tolerated, safe and efficacious."( Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group.
Duarte-Risselin, C; Leynadier, F; Murrieta, M,
)
0.39
" Safety was assessed by monitoring adverse events and laboratory parameters."( One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group.
Giannetti, A; Leynadier, F; Lorette, G; Murrieta-Aguttes, M; Pereira, RS, 2000
)
0.57
" There were no drug-related serious adverse events during the study."( One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group.
Giannetti, A; Leynadier, F; Lorette, G; Murrieta-Aguttes, M; Pereira, RS, 2000
)
0.57
" There were 27 adverse events, no serious adverse events in 177 patients during experimental period."( [Efficacy and safety of Mizolastine in the treatment of perennial allergic rhinitis].
Ding, J; Huang, Z; Wang, H; Zheng, C; Zhou, S, 2007
)
0.65

Pharmacokinetics

Mizolastine mean Cmax (SD) and median tmax were, respectively, 380 ng. The mean values of the pharmacodynamic parameters of apparent zero-order rate constant for the flare or wheal spontaneous appearance (k(in) were 14.5 ng in young healthy volunteers.

ExcerptReferenceRelevance
" The pharmacokinetic profile (rapid absorption with Tmax congruent to 1 h and elimination T1/2 of about eight hours) parallels the pharmacodynamic activity."( Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine.
Bianchetti, G; Caplain, H; Dubruc, C; Fuseau, E; Morselli, PL; Rosenzweig, P; Thebault, JJ, 1992
)
0.55
" The pharmacokinetic study included 11 plasma and 9 blister fluid samples and blister epidermal-roof specimens."( Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
Bianchetti, G; Chosidow, O; Danjou, P; Dubruc, C; Espagne, E; Fuseau, E; Herson, S; Revuz, J; Rosenzweig, P; Thenot, JP, 1996
)
0.51
"Mizolastine mean Cmax (SD) and median tmax were, respectively, 380 ng."( Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine.
Bianchetti, G; Chosidow, O; Danjou, P; Dubruc, C; Espagne, E; Fuseau, E; Herson, S; Revuz, J; Rosenzweig, P; Thenot, JP, 1996
)
1.96
"6 L and the mean terminal half-life was 12."( Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: noncompartmental approach and compartmental modeling.
Dubruc, C; Huet, S; Mallet, A; Mentre, F; Mesnil, F; Thenot, JP, 1997
)
0.59
" No change in AUC and tmax was recorded."( Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers.
Chaufour, S; Cimarosti, I; Delhotal-Landes, B; Denolle, T; Deschamps, C; Dubruc, C; Le Coz, F; Rosenzweig, P; Ulliac, N, 1998
)
0.63
"The aim of this work was to model the pharmacokinetic and pharmacodynamic relationship of mizolastine, a new H1-receptor antagonist obtained from histamine-induced wheal and flare inhibition test."( Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps, C; Dubruc, C; Mentre, F; Rosenzweig, P, 2000
)
0.78
" Pharmacokinetic and pharmacodynamic modeling were performed subject by subject for the 4 doses altogether by nonlinear regression."( Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps, C; Dubruc, C; Mentre, F; Rosenzweig, P, 2000
)
0.56
" The mean values of the pharmacodynamic parameters of apparent zero-order rate constant for the flare or wheal spontaneous appearance (k(in)), the first-order rate constant for the flare or wheal disappearance, the mizolastine concentration that produced 50% suppression of the maximum attainable inhibition of k(in), and the maximum attainable inhibition of the effect production were 14."( Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps, C; Dubruc, C; Mentre, F; Rosenzweig, P, 2000
)
0.75
"Pharmacokinetic and pharmacodynamic relationships of mizolastine were reliably described with the use of an indirect pharmacodynamic model; this led to an accurate prediction of the pharmacodynamic activity of mizolastine."( Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
Deschamps, C; Dubruc, C; Mentre, F; Rosenzweig, P, 2000
)
0.81
" Our objective was to design the population pharmacokinetic (PK) study of mizolastine pediatric solution in children."( Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Dubruc, C; Mentré, F; Thénot, JP, 2001
)
0.77
" In young healthy volunteers, absorption of mizolastine is rapid with time (tmax) to peak concentration (Cmax) of about 1 hour."( Clinical pharmacokinetics of mizolastine.
Chosidow, O; Diquet, B; Lebrun-Vignes, B, 2001
)
0.86
"5 × 10(-7)g/L based on a signal-to-noise of 3 (S/N=3) with 751- to 1372-fold increases in detection sensitivity for analytes, and it was successfully applied to the pharmacokinetic study of three antihistamines in human urine after an oral administration."( Trace analysis of three antihistamines in human urine by on-line single drop liquid-liquid-liquid microextraction coupled to sweeping micellar electrokinetic chromatography and its application to pharmacokinetic study.
Chen, G; Chen, Y; Gao, W; Xi, J; Xu, N; Yang, J, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
"0324), a new antihistaminic drug, in human plasma, three methods were developed based on liquid-liquid extraction, solid-phase extraction and column-switching in combination with high-performance liquid chromatography with ultraviolet detection."( Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid-liquid extraction, solid-phase extraction and column-switching techniques in combination with high-performance liquid chromatography.
Ascalone, V; Guinebault, P; Rouchouse, A, 1993
)
0.63

Bioavailability

absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77%. The estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.

ExcerptReferenceRelevance
" It has a good bioavailability and a metabolism via the cytochrome P-450 oxidation accounting for only 35% of its hepatic clearance."( The current cardiac safety situation with antihistamines.
Camm, AJ; Yap, YG, 1999
)
0.3
" A bioavailability study of this solution compared to the marketed tablet was performed in 18 young volunteers."( Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children.
Dubruc, C; Mentré, F; Thénot, JP, 2001
)
0.54
" The absolute bioavailability of mizolastine 10mg tablets is about 65%."( Clinical pharmacokinetics of mizolastine.
Chosidow, O; Diquet, B; Lebrun-Vignes, B, 2001
)
0.88
" The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine."( Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
Benedetti, MS; Diquet, B; Molimard, M, 2004
)
0.8
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The results showed a dose-response relationship: mizolastine 40 and 20 mg impaired driving and psychomotor performance."( Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers.
O'Hanlon, JF; Rosenzweig, P; Uiterwijk, MM; Vuurman, EF, 1994
)
0.93
" Histamine tests were performed on 10 occasions up to +24 h after dosing using an intradermal injection of histamine 2 micrograms with concommittant contralateral injection of a saline control."( Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers.
Cabanis, MJ; Caplain, H; Chaufour, S; Rosenzweig, P; Thebault, JJ; Ulliac, N, 1995
)
0.56
" To explain the kinetic variability, eight covariates were introduced in the analysis: gender, pharmaceutical dosage form, age, body weight, serum creatinine concentration, creatinine renal clearance, plasma levels of hepatic transaminases ASAT and ALAT."( Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.
Dubruc, C; Mallet, A; Mentré, F; Mesnil, F; Thénot, JP, 1998
)
0.57
"5, 1, 2, 3, 4, 6, 8, 12, 16, and 20 h after dosing and from day 2 to day 6, before dosing and 1, 2, 3, and 4 h after."( Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
Caplain, H; Chaufour, S; Deschamps, C; Dubruc, C; L'héritier, C; Lilienthal, N; Rosenzweig, P, 1999
)
0.54
"To compare the activity of antihistamines by the index of area under dose-response curve (AUDRC) obtained from histamine-induced wheal and flare reactions."( [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
Wang, RQ; Zhang, HY, 2004
)
0.32
"7 mmol/L) were performed for each one before dosing and 2, 4, and 24 hours after dosing."( [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
Wang, RQ; Zhang, HY, 2004
)
0.32
"9 ln (mmol/L) x mm2 at each time (before dosing and 2, 4, 24 hours after dosing) respectively."( [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
Wang, RQ; Zhang, HY, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Mizolastine H1-Antihistamine Action87

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346924
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
SMAD family member 3Homo sapiens (human)Potency9.52050.173734.304761.8120AID1346924
TDP1 proteinHomo sapiens (human)Potency10.59310.000811.382244.6684AID686978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency20.91730.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency13.80290.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency24.55210.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency13.33320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.31380.000229.305416,493.5996AID743069
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency10.00710.001024.504861.6448AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency10.68220.023723.228263.5986AID743223
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency1.77830.01789.637444.6684AID588834
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency28.22410.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency12.39720.004611.374133.4983AID624296; AID624297
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency7.94330.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)5.00000.00011.753610.0000AID432955
Cytochrome P450 2D6Homo sapiens (human)Ki20.00000.00011.19868.0000AID432951
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki10.00000.00000.59729.1201AID432950
DRattus norvegicus (Norway rat)IC50 (µMol)0.35480.00030.50267.7625AID243189
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.35480.00031.09147.7625AID243189
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.35480.00031.09147.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.35480.00031.06917.7625AID243189
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.35480.00070.97749.7000AID243189
Histamine H1 receptorHomo sapiens (human)Ki0.00270.00000.511010.0000AID432949
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.40580.00091.901410.0000AID161281; AID243151; AID243189; AID408340; AID420668; AID432952; AID576612; AID82355
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki7.25800.00211.840710.0000AID432953
Histamine H4 receptorHomo sapiens (human)Ki10.00000.00060.478710.0000AID1798265
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (122)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (57)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (78)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID432962Ratio of drug level in brain to plasma in rat at 1 mg/kg, iv after 2 hrs2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID432961Drug level in rat plasma assessed per gram of tissue at 1 mg/kg, iv after 2 hrs2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID432954Selectivity for human muscarinic M1 receptor over human histamine H1 receptor2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID432950Displacement of [3H]N-methyl Scopolamine from human muscarinic M1 receptor expressed in CHO Flp-In cells by liquid scintillation assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID432960Biodistribution in rat brain assessed per gram of tissue at 1 mg/kg, iv after 2 hrs2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID432963Biodistribution in rat brain at 1 mg/kg, iv after 2 hrs in presence of triprolidine2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID432953Displacement of [3H]dofetolide from human ERG channel expressed in HEK293 cells at 37 degC by liquid scintillation assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID432952Inhibition of human ERG channel expressed in HEK293 cells by patch clamp assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID432951Inhibition of CYP2D62009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID432955Inhibition of CYP3A42009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID432949Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1798265H4R Radioligand Binding Assay from Article 10.1124/jpet.105.087965: \\Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.\\2005The Journal of pharmacology and experimental therapeutics, Sep, Volume: 314, Issue:3
Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's42 (40.00)18.2507
2000's45 (42.86)29.6817
2010's12 (11.43)24.3611
2020's6 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.16 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index81.78 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (51.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials43 (39.81%)5.53%
Reviews7 (6.48%)6.00%
Case Studies5 (4.63%)4.05%
Observational0 (0.00%)0.25%
Other53 (49.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Bioequivalence Study of Home-made and Imported Mizolastine Tablets in Healthy Volunteers [NCT01928316]Phase 124 participants (Actual)Interventional2009-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]